Compare Amphastar Pharmaceuticals Inc (AMPH) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Marsh & McLennan Companies, Inc. trades at $191.32 (market cap $91.05B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 105.4× Amphastar Pharmaceuticals Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.08% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MRSH | |
|---|---|---|
Market Cap | $863.95M | $91.05B |
Sector | Health | Financials |
52-Week High | $30.81 | $211.21 |
52-Week Low | $16.87 | $157.32 |
Enterprise Value | $1.26B | $111.73B |
Dividend Yield | — | 2.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Marsh & McLennan (MRSH) trades at $191.65, down 0.85% on the day, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.96 exceeding expectations. Revenue growth remains solid at 6% in Q2 2026, while the company maintains healthy profitability with a 14.24% net income margin. Recent acquisitions and AI investments highlight strategic growth initiatives.
The outlook for MRSH is positive, supported by earnings momentum and a consensus price target of $202.89 offering potential upside. However, margin pressure from rising expenses and soft P&C pricing present near-term risks. Institutional activity shows mixed sentiment, with some firms increasing stakes while others reduce holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
